Drug Profile
Research programme: antioxidant therapeutics - OXIS International
Latest Information Update: 12 Feb 2015
Price :
$50
*
At a glance
- Originator OXIS Therapeutics
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Neurological disorders; Parkinson's disease
Most Recent Events
- 07 Apr 2006 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 07 Apr 2006 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
- 26 Mar 2004 OXIS International has been acquired by Axonyx